Edesa Biotech appoints Jennifer Chao to Board; grants 30,000-share option

Edesa Biotech, Inc.

Jennifer Chao appointed to fill board vacancy, effective March 28, 2022; term expires at 2022 annual meeting.
Chao granted option to purchase 30,000 common shares at $2.94/share, vesting monthly over 12 months.
She will serve on the Nominating and Compensation Committees.
Chao is Managing Partner of CoreStrategies Management and serves on boards of Endo International (ENDP) and Cardiol Therapeutics (CRDL).
Over 25 years biotech/life sciences experience; former managing director at Deutsche Bank, RBC Capital Markets.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Chao

Director

EDSA · Edesa Biotech, Inc.

Effective: 2022-03-28
Filed: March 29, 2022, 7:59 PM ET

the Board voted to appoint Jennifer Chao as a director of the Company to fill a vacancy on the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Chao was appointed as Director at Edesa Biotech, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board voted to appoint Jennifer Chao as a director of the Company to fill a vacancy on the Board

View on SEC.gov

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-003966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.